SAJAZIR

Live / Registered — Registered (as of 13 Jun 2023)

What this means for you

Registered since 13 Jun 2023. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
90461564
Registration number
7081259
Mark type
Stylized text
Filed
12 Jan 2021
Published for opposition
23 Aug 2022
Registered
13 Jun 2023
Attorney of record
Mary Frances Love

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical agents for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; pharmaceutical preparations for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; pharmaceuticals for the treatment of hereditary angioedema all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; Veterinary preparations for treatment of intestinal bacteria; veterinary preparations, namely, antioxidants; veterinary preparations, namely, pain relief medications; veterinary preparations for medical treatment of chronic illnesses; veterinary preparations for treatment of viral diseases; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use; dietary supplements for humans and animals; supplements for the treatment of hereditary angioedema; supplements for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; food for babies; medical dressings; plasters for medical purposes; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides; biological preparations for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels and transdermal patches; chemical preparations for the medical treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels and transdermal patches; Drug delivery agents consisting of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents for use in pharmaceutical preparations, drugs and medicines for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; medical drugs for the treatment of rare diseases, in particular for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; enzyme preparations for medical purposes, enzyme preparations for the treatment of hereditary angioedema, medical enzyme preparations in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; enzyme preparations for veterinary purposes; medicinal preparations for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; medicines for the treatment of hereditary angioedema, all in the form of liquids, topical solutions, liquid suspensions, syrups, drops, capsules, tablets, caplets, powders, compressed tablets, dispersible tablets, inhaled vapors, gases, and mists, topical creams and gels, and transdermal patches; Medical and veterinary preparations and articles, namely, pre-filled syringes containing a bradykinin B2 receptor antagonist for medical purposes; Pharmaceuticals and natural remedy preparations, for use in the treatment and management of hereditary angioedema; single-use pre-filled syringes containing a bradykinin B2 receptor antagonist; syringes sold filled with a bradykinin B2 receptor antagonist for subcutaneous injections in the treatment of acute attack of hereditary angioedema; single-use pre-filled syringes containing a bradykinin B2 receptor antagonist for subcutaneous injections in the treatment of acute attack of hereditary angioedema

Owner

Prosecution history

  • 13 Jun 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
  • 13 Jun 2023 — REGISTERED-PRINCIPAL REGISTER
  • 09 May 2023 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
  • 08 May 2023 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
  • 04 May 2023 — STATEMENT OF USE PROCESSING COMPLETE
  • 18 Apr 2023 — USE AMENDMENT FILED
  • 04 May 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
  • 18 Apr 2023 — TEAS STATEMENT OF USE RECEIVED
  • 18 Oct 2022 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 23 Aug 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 23 Aug 2022 — PUBLISHED FOR OPPOSITION
  • 03 Aug 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 15 Jul 2022 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 14 Jul 2022 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 14 Jul 2022 — CORRESPONDENCE RECEIVED IN LAW OFFICE

View this trademark record on Marksy